Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
Across 13 preclinical small molecule metabolic deals, the median upfront payment is $115M with a P25–P75 range of $75M–$285M. The spread is massive — and the drivers are identifiable. Here's how to benchmark your asset.
The median upfront for an approved small molecule women's health deal is $875M across 19 transactions, but the P25–P75 spread runs from $174M to $1.8B. Here's what drives that 10x range — and where your asset likely lands.
The median upfront for an approved rare disease deal sits at $3,050M across 17 comparable transactions, with a striking P25–P75 range of $450M to $11,600M. Here's what drives that 25x spread and where your asset likely falls.
The median upfront for an approved small molecule infectious disease deal is $139M, based on 8 completed transactions. The interquartile range spans $75M to $318M — a 4x spread driven by competitive positioning, portfolio urgency, and regulatory differentiation.
The median upfront for a preclinical small molecule immunology deal is $190M across 16 analyzed transactions, with a P25–P75 range of $61M to $333M. Here's what drives the spread and how to position your asset.
The median upfront for a preclinical gene therapy ophthalmology deal is $40M across 7 benchmarked transactions, with a P25–P75 range of $20M–$50M. Here's what drives the spread and how to position your asset.
The median upfront for a preclinical gene therapy neurology deal is $73M across 28 transactions, but the interquartile range spans $39M to $165M. What separates the bottom quartile from the top — and where does your asset land?
The median upfront for an approved CDMO metabolic deal is $1,847M, but the interquartile range spans $604M to $6,300M — a 10x spread driven by asset differentiation, manufacturing infrastructure value, and buyer urgency. Here's how to benchmark your deal against the data.
The median upfront for an approved small molecule ophthalmology deal is $1,750M across 11 benchmarked transactions, with a P25–P75 range spanning $760M to $5,200M. This article breaks down what drives that spread and how to position your asset accordingly.
The median upfront for an approved small molecule hematology deal is $2000M, based on 7 completed transactions. But the interquartile range spans $1800M to $5100M — a $3.3B gap driven by competitive positioning, commercial traction, and buyer urgency.
The median upfront for a preclinical mRNA infectious disease deal is $75M across 11 analyzed transactions, but the interquartile range spans $26M to $163M. Where your asset lands in that range depends on mechanism differentiation, buyer urgency, and competitive landscape density.
The median upfront for an approved small molecule cardiovascular deal sits at $350M, but the P25–P75 range spans $185M to $13.1B. That 70x spread tells you everything about how asset differentiation, competitive dynamics, and buyer strategy reshape deal economics in this space.
The median upfront for a preclinical gene therapy cardiovascular deal is $98M, based on 10 comparable transactions. But the P25–P75 spread of $62M–$224M tells a more important story about what actually drives pricing at this stage.
The median upfront for a preclinical peptide dermatology deal is $525M, with a P25–P75 range of $163M to $950M across 4 benchmarked transactions. Here's what drives the 6x spread and where your asset likely falls.
The median upfront for a preclinical oligonucleotide gastroenterology deal sits at $35M, based on 5 comparable transactions from 2023–2025. But the range stretches to $60M at P75 — and one outlier hit $150M. Here's what drives the spread and how to position your asset.
The median upfront for an approved monoclonal antibody immunology deal sits at $8,700M across 7 benchmarked transactions. The interquartile range spans $4,650M to $24,250M — a $19.6B gap driven by competitive positioning, franchise value, and buyer urgency. Here's how to read the data and position your asset.
The median upfront for an approved small molecule neurology deal sits at $1,375M across 10 recent transactions — but the spread from $485M to nearly $6B at the quartiles tells a more important story. Here's exactly what drives that range and where your asset likely falls.
The median upfront for an approved small molecule dermatology deal is $612M, based on 5 benchmarked transactions with a P25–P75 range of $540M–$1.2B. Here's what drives the spread and how to position your asset at the top of the range.
The median upfront for a preclinical bispecific antibody oncology deal is $55M across 58 analyzed transactions, with a P25–P75 range of $37M–$95M. Here's what drives the spread and how to position your asset at the top of it.
The median upfront for an approved small molecule oncology deal is $2,400M across 23 analyzed transactions, with a P25–P75 range spanning $588M to $11,500M. Here's what drives that 20x spread and where your asset likely falls.
The median upfront for a preclinical gene therapy rare disease deal is $185M across 12 transactions, but the P25–P75 spread runs from $42M to $1,025M. That 24x gap tells you more about deal dynamics than any single headline number. Here's what drives it and where your asset likely falls.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.
Try Solidus
